A New Gene Delivery Platform
Recombinant viral vectors have been utilized in the settings of gene therapy, vaccination and immunotherapy but have encountered clinical challenges because they are recognized as foreign entities to the host. This recognition leads to an immunologic clearance of the vector and the inserted gene of interest. Etubics has reported on a new viral vector technology that can be utilized as an immunization modality to induce immune responses even in the presence of vector immunity. We have reported immunization and immunotherapy results to infectious diseases and cancers. This improved viral platform, Ad5 [E1-, E2b-], can be utilized in the development of multiple vaccines and immunotherapies.
Etubics is currently developing therapeutic products to treat or protect against the following diseases:
Vaccines stimulates the body’s immune system to recognize the agent as a threat, destroy it, and keep a record of it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. They have historically been the most effective means to fight and eradicate infectious diseases. Etubics has created novel vaccines against infectious and emerging diseases using our Etubics Platform. The Etubics Platform has been shown to induce both arms of the immune system – cell mediated immunity, or CMI, and antibodies. CMI, which involves the production by the body of killer T-cells that attack the desired disease target, enables a long-lasting immune response even after the therapeutic administered is no longer present in the body. We have created and continue to investigate several preventative vaccines against infectious diseases such as Influenza and HIV as well as emerging pathogens such as H1N1, Chikungunya and Ebola.
Etubics is currently developing the following against infectious diseases: